Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Liver Cancer

Liver Cancer

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Liver Cancer

184 trials tracked for Liver Cancer: 21 in phase 3 or 4 and 12 with published results. The most-cited published study has 254 citations.

184Trials tracked
21Phase 3 & 4
0Recruiting
12With published results
Phase distribution
Phase 4 3 Phase 3 18 Phase 2 113 Phase 1 13 Other / NA 37
  1. Phase 3 Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy Completed · 254 cited
  2. Phase 3 A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC) Completed · 241 cited
  3. Phase 3 A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma Completed · 152 cited
  4. Phase 3 Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers Completed · 129 cited
  5. Phase 3 Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer Completed · 119 cited
  6. Phase 4 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed · 112 cited
Show 44 more trials
  1. Phase 3 Postoperative Thoracic Epidural Analgesia Versus Intravenous Patient-Controlled Analgesia For Liver and/or Pancreas Completed · 86 cited
  2. Phase 3 Clinical Trial of Standard Versus Goal-Directed Perioperative Fluid Management (GDT) for Patients Undergoing Liver Resection Completed · 81 cited
  3. Phase 3 Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer Completed · 69 cited
  4. Phase 3 Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers Completed · 46 cited
  5. Phase 3 Chemoembolization of the Liver With or Without Sunitinib Malate in Treating Patients With Liver Cancer Completed · 20 cited
  6. Phase 3 Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival Completed · 8 cited
  7. Phase 4 SIR-Spheres Study to Calculate the Radiation-Absorbed Dose of 99mTc-MAA Completed
  8. Phase 4 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed
  9. Phase 3 SonoVue®-Enhanced Ultrasound Versus Unenhanced US for Focal Liver Lesion Characterization Completed
  10. Phase 3 SonoVue®-Enhanced Ultrasound (US) Versus Unenhanced US for Focal Liver Lesion Characterization Completed
  11. Phase 3 Study of Peretinoin for Suppressing Recurrence of HCV-positive HCC Completed
  12. Phase 3 Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone Completed
  13. Phase 3 A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer Completed
  14. Phase 3 De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma Completed
  15. Phase 3 Comparing Irinotecan and 5 FU/FA To 5-FU/FA After Resection Of Liver Metastases For Colorectal Cancer Completed
  16. Phase 2 Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma Completed
  17. Phase 2 A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation Completed
  18. Phase 2 Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma Completed
  19. Phase 2 Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome Completed
  20. Phase 2 Study of BGB-A317 in Participants With Previously Treated Unresectable HCC Completed
  21. Phase 2 Pembrolizumab (MK-3475) in Hepatocellular Carcinoma Completed
  22. Phase 2 IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC) Completed
  23. Phase 2 Cisplatin or Carboplatin and Sorafenib in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery Completed
  24. Phase 2 Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma Completed
  25. Phase 2 Phase II Trial Evaluating OS With Therasphere® + 2nd-Line FOLFOX in Pancreatic Liver Mets Completed
  26. Phase 2 Bupropion in Helping Adults Stop Smoking Completed
  27. Phase 2 Sorafenib + mFOLFOX for Hepatocellular Carcinoma Completed
  28. Phase 2 Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma Completed
  29. Phase 2 MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery Completed
  30. Phase 2 Magnetic Resonance Elastography and 2-Point Dixon MR Imaging Techniques in Diffuse Liver Disease Completed
  31. Phase 2 Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC) Completed
  32. Phase 2 Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery Completed
  33. Phase 2 Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers Completed
  34. Phase 2 A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC) Completed
  35. Phase 2 A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma Completed
  36. Phase 2 Survivorship Promotion In Reducing IGF-1 Trial Completed
  37. Phase 2 Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver Completed
  38. Phase 2 A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) in Patients With Advanced or Metastatic Liver Cancer Completed
  39. Phase 2 Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy Completed
  40. Phase 2 Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer Completed
  41. Phase 2 Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer Completed
  42. Phase 2 Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By Surgery Completed
  43. Phase 2 Bevacizumab and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery Completed
  44. Phase 2 IMC-A12 in Treating Patients With Advanced Liver Cancer Completed

Showing the 50 most-cited and recently-updated of 184 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Epigallocatechin-3-gallate shows positive therapeutic effects on various digestive system diseases in animal models
Oncology Meta-analysis
Epigallocatechin-3-gallate shows positive therapeutic effects on various digestive system diseases in animal models Green tea compound shows potential for several digestive diseases
This meta-analysis of 63 preclinical studies involving 738 animals indicates that Epigallocatechin-3-gallate (EGCG) has a positive therapeut…
A review of animal studies suggests a green tea compound could help treat various cancers and digestive conditions.
Frontiers Jun 11, 2026
Narrative review of lung, breast, liver, and kidney cancer evidence
Urology Meta-analysis
Narrative review of lung, breast, liver, and kidney cancer evidence New Cancer Tests Could Spot Tumors Years Earlier Than Before
This narrative review synthesizes published English-language evidence on lung, breast, liver, and kidney cancers. The authors note the scope…
A new wave of cancer biomarker tests can spot lung, breast, liver, and kidney tumors years earlier, opening the door to faster treatment and…
Frontiers May 9, 2026